14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
LCTX vs JSPR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Jasper Therapeutics, Inc. (JSPR) captures the overall head-to-head institutional edge over Lineage Cell Therapeutics, Inc. (LCTX) on higher Unified Composite conviction (33.8/100 SELL vs. 58.9/100 HOLD) after splitting the core matrix 3–7 (led by Balance Sheet & Cash Flow, Options & Positioning), while LCTX wins 3–2 across the 6-pillar growth and valuation breakdown. LCTX trades at $0.82 (30.7x Forward P/E, -280.3% operating margin) versus JSPR at $10.75 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (58.9/100 HOLD vs. JSPR 33.8/100 SELL), JSPR captures the overall institutional head-to-head verdict (3–7 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -280.3% operating margin) and revenue trajectory (+0.0% vs. -61.0% YoY).
Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.1); meanwhile JSPR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LCTX vs JSPR. Trailing 12-month operating profitability (LCTX -280.3% vs JSPR 0.0%) and valuation multiples (LCTX 30.7x vs JSPR N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $12.8M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ LCTX vs JSPR Key Questions & Quantitative Answers
As of Nov 19, 2026, Jasper Therapeutics, Inc. (JSPR) captures the overall head-to-head institutional edge over Lineage Cell Therapeutics, Inc. (LCTX) on higher Unified Composite conviction (33.8/100 SELL vs. 58.9/100 HOLD) after splitting the core matrix 3–7 (led by Balance Sheet & Cash Flow, Options & Positioning), while LCTX wins 3–2 across the 6-pillar growth and valuation breakdown. LCTX trades at $0.82 (30.7x Forward P/E, -280.3% operating margin) versus JSPR at $10.75 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (58.9/100 HOLD vs. JSPR 33.8/100 SELL), JSPR captures the overall institutional head-to-head verdict (3–7 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -280.3% operating margin) and revenue trajectory (+0.0% vs. -61.0% YoY). Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.1); meanwhile JSPR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
LCTX leads the Growth & Scale pillar: LCTX posts -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin), compared with JSPR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, LCTX generates $11M in USD-normalized revenue versus N/A for JSPR. In operating R&D and SG&A reinvestment, LCTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for JSPR.
LCTX screens cheaper on headline valuation multiples. LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 16.3x EV/Revenue (unreported FCF margin), whereas JSPR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LCTX (4.3% ROE) versus JSPR (-255.1% ROE) capital efficiency.
In options market volatility and institutional positioning, LCTX carries 896.2% implied volatility (100th %ile, Extreme (>80th %ile)), a 1.10x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.36β · 79% Vol realized risk). By comparison, JSPR carries 439.3% implied volatility (45th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (8.00β · 11818% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.